Cigna (CI) shares dropped over 10% after Q2 2025 results, but TD Cowen analyst Charles Rhyee sees it as a buying opportunity, maintaining a Buy rating with a $387 price target. He believes recent pullback was overdone and deems current levels attractive for entry.

Rhyee expects Cigna’s strength in Specialty and Care Services, as well as solid momentum in Pharmacy Benefit Management (PBM) to offset Health Insurance Exchange (HIX) segment concerns. He notes management’s cautious Q3 guidance but remains confident in the company’s earnings outlook with robust EPS growth projections.

Cigna Group (NYSE:CI) provides medical, pharmacy, behavioral health, dental, and supplemental insurance products. While CI shows investment potential, some believe certain AI stocks offer greater upside potential and less downside risk. For those interested in an undervalued AI stock, see a free report on the best short-term AI stock.

For more insights, check out “10 Most Oversold S&P 500 Stocks So Far in 2025” and “10 Most Oversold Semiconductor Stocks So Far in 2025” on Insider Monkey’s website. This article is not sponsored.

Read more at Yahoo Finance: Cigna (CI) Pullback a Buying Opportunity, Says TD Cowen with a Buy Rating